amct enhanced glp-1

---

GLP-1 receptor agonists have redefined the treatment of diabetes, obesity, and metabolic disease. They are, without question, one of the most successful therapeutic classes ever developed. But there is a catch: every single one of the leading products requires an injection. For many patients, that’s where the story ends.

Attempts to move GLP-1 therapies into oral form have been made, most prominently semaglutide delivered with the SNAC excipient. That experiment proved that oral dosing was possible, but it came at a steep price: extremely low bioavailability (~1%), high patient-to-patient variability, strict fasting requirements, and doses measured in tens of milligrams.

Zoom Biotech’s AMCT Novel Drug Delivery System (NDDS) represents a clean break from this model. Instead of brute forcing absorption by irritating the stomach lining and altering pH, NDDS protects and guides peptides through a controlled, physiologic pathway. It supports both orally disintegrating tablets (ODT) and capsules, giving patients flexibility and giving clinicians consistent, predictable dosing.

Preliminary data already show that NDDS can deliver clinically meaningful reductions in fasting blood glucose and body weight at microgram-level doses — as low as 0.07 mg/day. That’s not just a modest improvement over SNAC; it’s a complete reimagining of what oral peptide delivery can be. With a bioavailability target of ~50%, NDDS has the potential to bring GLP-1 therapies into oral form at a scale and efficiency that makes them viable for the long term — and to extend that same innovation across other classes of biologics.